Immunohistochemical Study of Metalloproteinases (MMP-2 and MMP-9) Expression in Laryngeal Squamous Cell Carcinoma EF01-EF05
Dr. Mai Omar Elfarouk Elsherbeiny,
Department of Pathology, Faculty of Medicine, Cairo University, 1084 Forth District- 6-October, Giza, Cairo, Egypt.
Introduction: Laryngeal squamous cell carcinoma (LSCC) is the second most common head and neck Squamous cell carcinoma (SCC). Among more than 24 members of the Matrix metalloproteinases (MMPs) family, MMP-2 and MMP-9 are proved to have the capacity to degrade the most important elements of Extracellular matrix (ECM) and basement membrane, thus contributing to the invasion and metastases of the malignant tumours.
Aim: To evaluate and compare Immunohistochemistry (IHC) stained sections of MMP-2 and MMP-9 in both in situ and invasive LSCC and to study its relation with other clinicial and pathological features.
Materials and Methods: This was a retrospective cross-sectional study conducted in Pathology department, Facutly of Medicine, Cairo University. A total of 60 specimens LSCC were studied obtained from laryngsopyic biopsies, partial and total laryngectomy specimens with selective neck dissection over one year duration. Both Haematoxylin and Eosin (H&E) and IHC (MMP-2 and MMP-9) stained sections were evaluated. IHC results of MMP-2 and MMP-9 were correlated with clinicopathological parameters. Data was analysed using SPSS software version 17.0. The p-value <0.05 was considered as statistically significant.
Results: Thirty five (35) cases (58.3%) were considered MMP-2 expressors and 36 cases (60%) were considered MMP-9 expressors. A significant relations were detected between MMP-2 and MMP-9 expressions on one hand and tumour grading, tumour site, infiltration of thyroid cartilage, infiltration of resected margins, lymph node metastasis and tumour staging on the other hand (p-value <0.05).
Conclusion: MMP-2 and MMP-9 overexpression could be a useful prognostic marker for predicting LSCC with a potential for metastatic behaviour. This allows easier identification of patients who are at higher risk of metastatic carcinoma and should be controlled more frequently. Larger studies on a wider scale of patients are needed based on long term follow-up.